

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-10. (Cancelled).

11. (Currently Amended) An isolated polypeptide of any one of (a) to ~~(e)~~ (b) described below:

(a) a polypeptide comprising ~~the~~ an amino acid sequence of any one of SEQ ID NOs: 1 and 3 to 12 ~~1 to 12~~; and

(b) a polypeptide comprising a peptide region cyclized by a disulfide bond formed between cysteine residues on both ends of the polypeptide of (a); ~~and~~

~~(c) a polypeptide having brain localizing activity, and comprising an amino acid sequence with one or several amino acid additions, deletions, or substitutions in the amino acid sequence of any one of SEQ ID NOs: 1 to 12.~~

12. (Currently Amended) The polypeptide of ~~any one of claims 1 to 11~~ claim 11, wherein the length of the polypeptide is 9 amino acids or less.

13.-14. (Cancelled).

15. (Currently Amended) A pharmaceutical agent for conferring brain-localizing activity to an arbitrary molecule, wherein the agent comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

16. (Original) The pharmaceutical agent of claim 15, wherein the arbitrary molecule is an arbitrary polypeptide.

17. (Currently Amended) A molecule having brain-localizing activity, wherein the molecule comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

18. (Original) The molecule of claim 17, wherein the molecule is a phage particle or a coat protein of a phage particle.

19. (Currently Amended) The molecule of claim 17, wherein the molecule is a fusion protein formed with the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

20. (Currently Amended) A carrier for delivery to the brain, wherein the carrier comprises the polypeptide of ~~any one of claims 1 to 12~~ claim 11.

21. (Currently Amended) A carrier for delivery to the brain, wherein the carrier comprises a structure in which the polypeptide of ~~any one of claims 1 to 12~~ claim 11 is bound to a micelle, liposome, or microcapsule.

22. (Original) A therapeutic agent for brain disease, wherein the agent comprises a structure in which a drug is supported by the carrier of claim 20 or 21.

23. (Currently Amended) A method for producing a molecule having brain-localizing activity, wherein the method comprises binding ~~the polypeptide of any one of claims 1 to 12~~ to an arbitrary molecule a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12.

24. (Cancelled).

25. (Currently Amended) A method for translocating an arbitrary molecule into the brain of ~~a non-human~~ an animal, wherein the method comprises the steps of:

(a) producing a molecule having brain-localizing activity, wherein the molecule comprises a structure in which an arbitrary molecule is bound to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12 ~~the polypeptide of any one of claims 1 to 12~~; and

(b) administering the molecule into the body of the ~~non-human~~ animal.

26. (Withdrawn - Currently Amended) A method of screening for a molecule having binding activity to a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12 ~~the polypeptide of any one of claims 1 to 12~~, wherein the method comprises the steps of:

- (a) contacting ~~the polypeptide of any one of claims 1 to 12~~ with a test molecule a polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 1 to 12;
- (b) detecting binding activity between the polypeptide and the test molecule; and
- (c) selecting a molecule that binds to the polypeptide.

27. (Withdrawn) A method of screening for a polypeptide having brain-localizing activity, wherein the method comprises the steps of:

- (a) preparing a phage particle displaying a test polypeptide on its phage coat protein;
- (b) administering the phage particle to a non-human animal;
- (c) collecting a phage particle from a brain tissue of the non-human animal; and
- (d) selecting a test polypeptide displayed on the phage particle collected in step (c) as a polypeptide having brain-localizing activity.

28. (Withdrawn – Currently Amended) The method of claim 27, wherein the test polypeptide comprises ~~the~~ an amino acid motif sequence of any one of SEQ ID NOs: 1 to 12 ~~any one of claims 5, 7, and 8~~.

29. (Withdrawn) The method of claim 27, wherein the phage is M13 phage or T7 phage.

30. (Withdrawn – Currently Amended) The method of claim 27, wherein the method further comprises selecting a phage particle that binds to a ~~erebrovascular~~ cerebrovascular endothelial cell subsequent to step (a).